Capricor Therapeutics Faces Class Action Lawsuit
Purchasers of Capricor Therapeutics securities have until September 28, 2026, to lead a class action lawsuit alleging securities law violations. Investors with substantial losses are eligible.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing a class action lawsuit concerning its securities transactions between December 17, 2025, and July 26, 2026. The lawsuit alleges that the company violated securities laws during this period.
Investors who incurred substantial losses from purchasing or acquiring Capricor securities within the specified class period are invited to seek appointment as lead plaintiff. The suit centers on allegations that Capricor Therapeutics made misleading or false statements about its business and future prospects.
Interested parties who suffered losses must file their intent to lead the lawsuit by the September 28, 2026 deadline. This legal action aims to consolidate claims and seek recovery for investors impacted by the alleged misrepresentations.
This development could have implications for Capricor Therapeutics' reputation and stock performance. The company is expected to respond to the allegations as the legal proceedings advance.